Questioning the role of palmitoylethanolamide in psychosis: a systematic review of clinical and preclinical evidence
ReviewHumans
- Design
- Review
- Subjects
- 13 studies: 11 in people and 2 in animals
- Dose used in the study
- The supplementation studies used 600 mg once or twice a day for 8 to 12 weeks
- What was measured
- Levels of palmitoylethanolamide in people with psychosis, and the effects of supplementation
What the authors reported
This systematic review found:
- Six observational studies found raised plasma levels of palmitoylethanolamide in people with psychosis, described as a possible early compensatory response.
- One study found palmitoylethanolamide levels raised in the central nervous system too, though this rise seemed to be lost over the longer term.
- Three studies of supplementation reported reduced negative psychotic and manic symptoms, with no serious adverse events.
- The two animal models showed no change in palmitoylethanolamide.
Limits of this study
A systematic review without a pooled analysis. Only three of the studies tested supplementation. One author (Colizzi) declares consulting for GW Pharma and Roche, outside this work; the others declared no conflict. The authors' stated limitations and funding were not visible on the page checked.
Source
PubMed 37533892 · doi:10.3389/fpsyt.2023.1231710
Entry checked against the full text at the publisher (Frontiers) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.